Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,501 to 4,520 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| MiStent® vs XIENCE EES: POCE | 93 of 703 101 of 695 | -1.3 points -4.9 to 2.3 | 1,398 | NCT02385279 Study Comparing the MiStent SES Versus the XIENCE EES Stent |
| MiStent® vs XIENCE EES: Stent Thrombosis | 5 of 703 6 of 695 | -0.2 points -1.2 to 0.9 | 1,398 | NCT02385279 Study Comparing the MiStent SES Versus the XIENCE EES Stent |
| MiStent® vs XIENCE EES: Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE) | 40 of 703 45 of 695 | -0.8 points -3.3 to 1.7 | 1,398 | NCT02385279 Study Comparing the MiStent SES Versus the XIENCE EES Stent |
| MiStent® vs XIENCE EES: Any Revascularization | 61 of 703 78 of 695 | -2.5 points -5.7 to 0.6 | 1,398 | NCT02385279 Study Comparing the MiStent SES Versus the XIENCE EES Stent |
| MiStent® vs XIENCE EES: Target Vessel Failure (TVF) | 45 of 703 53 of 695 | -1.2 points -3.9 to 1.5 | 1,398 | NCT02385279 Study Comparing the MiStent SES Versus the XIENCE EES Stent |
| MiStent® vs XIENCE EES: deaths from any cause | 85 of 703 78 of 695 | 0.9 points -2.5 to 4.2 | 1,398 | NCT02385279 Study Comparing the MiStent SES Versus the XIENCE EES Stent |
| MiStent® vs XIENCE EES: MACE | 65 of 703 65 of 695 | -0.1 points -3.2 to 3.0 | 1,398 | NCT02385279 Study Comparing the MiStent SES Versus the XIENCE EES Stent |
| MiStent® vs XIENCE EES: serious adverse events | 434 of 703 426 of 695 | 0.4 points -4.6 to 5.5 | 1,398 | NCT02385279 Study Comparing the MiStent SES Versus the XIENCE EES Stent |
| Azithromycin (n=702) vs Placebo (n=696): deaths from any cause | 15 of 702 19 of 696 | -0.6 points -2.3 to 1.1 | 1,398 | NCT02414399 Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children |
| Azithromycin (n=702) vs Placebo (n=696): serious adverse events | 52 of 702 54 of 696 | -0.4 points -3.2 to 2.5 | 1,398 | NCT02414399 Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children |
| Pembrolizumab/Vibostolimab vs Pembrolizumab: serious adverse events | 109 of 698 57 of 700 | 7.5 points 4.1 to 10.9 | 1,398 | NCT05665595 A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) |
| Egg-derived Vaccine (TIV) vs Cell Culture-derived Vaccine (cTIV): serious adverse events | 10 of 396 20 of 1,001 | 0.5 points -1.0 to 2.7 | 1,397 | NCT00560066 Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions |
| GFRS EPD vs GEF EPD: serious adverse events | 18 of 425 36 of 972 | 0.5 points -1.5 to 3.1 | 1,397 | NCT01343667 GORE Flow Reversal System and GORE Embolic Filter Extension Study |
| C31G vs Conceptrol: serious adverse events | 10 of 836 12 of 560 | -0.9 points -2.6 to 0.4 | 1,396 | NCT00274261 Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol® |
| Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active Treatment Phase: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry | 887 of 891 501 of 504 | 0.1 points -0.7 to 1.3 | 1,395 | NCT01707992 The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) |
| Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active Treatment Phase: Number of Participants With Potentially Clinically Significant Abnormal Hematology Values | 886 of 891 499 of 504 | 0.4 points -0.5 to 1.8 | 1,395 | NCT01707992 The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) |
| Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active-Treatment Phase: Number of Participants With AEs | 442 of 891 241 of 504 | 1.8 points -3.7 to 7.2 | 1,395 | NCT01707992 The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) |
| Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active-Treatment Phase: Number of Participants With Clinically Significant Vital Signs Abnormalities | 17 of 891 7 of 504 | 0.5 points -1.1 to 1.9 | 1,395 | NCT01707992 The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) |
| Enzalutamide 160 mg vs Placebo: Number of Participants With Treatment-Emergent Adverse Events Greater Than or Equal to Grade 3, Based on National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE), Version 4.0 | 292 of 930 109 of 465 | 8.0 points 3.0 to 12.7 | 1,395 | NCT02003924 Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer |
| Enzalutamide 160 mg vs Placebo: Number of Participants With Discontinuations From Study Treatment Due to Adverse Events (AEs) | 87 of 930 28 of 465 | 3.3 points 0.3 to 6.1 | 1,395 | NCT02003924 Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer |
Code
curl "https://conductscience.org/api/comparisons/v1?page=226"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=226
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02385279-7790b5b8",
"title": "MiStent® vs XIENCE EES: POCE",
"summary": "93 of 703 against 101 of 695; risk difference -1.3 points, 95% interval -4.9 to 2.3; NCT02385279, Study Comparing the MiStent SES Versus the XIENCE EES Stent",
"record": "/library/comparisons/NCT02385279-7790b5b8",
"nct_id": "NCT02385279",
"kind": "outcome",
"participants": 1398,
"risk_difference": {
"value": -0.013033556085430387,
"lower": -0.04942305757177576,
"upper": 0.02330034650600197
},
"group_1": "93 of 703",
"group_2": "101 of 695",
"difference": "-1.3 points",
"interval": "-4.9 to 2.3",
"trial_title": "Study Comparing the MiStent SES Versus the XIENCE EES Stent"
},
{
"id": "NCT02385279-8863de09",
"title": "MiStent® vs XIENCE EES: Stent Thrombosis",
"summary": "5 of 703 against 6 of 695; risk difference -0.2 points, 95% interval -1.2 to 0.9; NCT02385279, Study Comparing the MiStent SES Versus the XIENCE EES Stent",
"record": "/library/comparisons/NCT02385279-8863de09",
"nct_id": "NCT02385279",
"kind": "outcome",
"participants": 1398,
"risk_difference": {
"value": -0.0015207179917516907,
"lower": -0.012384792276822246,
"upper": 0.009000833239810017
},
"group_1": "5 of 703",
"group_2": "6 of 695",
"difference": "-0.2 points",
"interval": "-1.2 to 0.9",
"trial_title": "Study Comparing the MiStent SES Versus the XIENCE EES Stent"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=227",
"request_id": "l2zZOs11PEl7bD0W"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant